Management ChangeMay 29, 2026, 04:14 PM
LENSAR Appoints Michael A. Rossi as Interim CFO; Sets Annual Meeting Date
AI Summary
LENSAR, Inc. announced the appointment of Michael A. Rossi as its Interim Chief Financial Officer, effective May 29, 2026. Mr. Rossi brings extensive experience from various healthcare and life sciences companies, including Harvard Bioscience, and will be provided through a consulting agreement with Monomoy Advisors LLC. Additionally, the company scheduled its 2026 annual meeting of stockholders for August 4, 2026, to be held virtually, and set revised deadlines for stockholder proposals and director nominations for June 8, 2026.
Key Highlights
- LENSAR appointed Michael A. Rossi as Interim Chief Financial Officer, effective May 29, 2026.
- Mr. Rossi previously served as CFO for Access Vascular, ConcertAI LLC, and Harvard Bioscience, Inc.
- He brings over twenty years of public company and private equity finance and accounting experience.
- Monomoy Advisors LLC will provide Mr. Rossi's services for a cash retainer of $375 per hour.
- The 2026 annual meeting of stockholders is scheduled for August 4, 2026, to be held virtually.
- Record date for voting at the 2026 Annual Meeting is June 10, 2026.
- Stockholder proposals for inclusion in the proxy statement are due by June 8, 2026.
- Stockholder director nominations and universal proxy notices are also due by June 8, 2026.
Price Impact
More from LNSR